| 独晓燕,潘 彬,周 星,王志民,王晓慧,要慧萍.血清cTnI、TFF1检测在乳腺癌化疗相关心脏毒性预测中的价值[J].现代生物医学进展英文版,2021,(24):4733-4736. |
| 血清cTnI、TFF1检测在乳腺癌化疗相关心脏毒性预测中的价值 |
| The Value of Serum cTnI and TFF1 Detection in the Prediction of Breast Cancer Chemotherapy-related Cardiotoxicity |
| Received:April 24, 2021 Revised:May 21, 2021 |
| DOI：10.13241/j.cnki.pmb.2021.24.027 |
| 中文关键词: 乳腺癌 蒽环类药物 心脏毒性反应 心肌肌钙蛋白I 三叶因子1 预测价值 |
| 英文关键词: Breast cancer Anthracyclines Cardiotoxicity Cardiac troponin I Trefoil factor 1 Predictive value |
| 基金项目:国家自然科学基金项目（81660803） |
|
| Hits: 611 |
| Download times: 342 |
| 中文摘要: |
| 摘要 目的：探讨血清心肌肌钙蛋白I（Cardiac，Troponin I，cTnI）、三叶因子1（trefoil factor 1，TFF1）检测在乳腺癌化疗相关心脏毒性预测中的价值。方法：2018年2月到2021年2月选择在本院接受蒽环类药物化疗的乳腺癌患者122例作为研究对象，所有患者都给予蒽环类药物化疗，在化疗前检测血清cTnI、TFF1含量，在化疗4个周期后观察心脏毒性反应发生情况并进行预测价值分析。结果：122例乳腺癌患者根据表阿霉素化疗累积剂量分为低剂量组（450-500 mg/m2）70例、中剂量组（501-550 mg/m2）30例、高剂量组（>550 mg/m2）22例；三组化疗前的血清cTnI、TFF1含量对比差异无统计学意义（P>0.05）。低剂量组、中剂量组、高剂量组化疗后的心电图异常率分别为1.4 %、13.3 %和22.7 %，对比差异有统计学意义（P<0.05）。在122例患者中，Pearson分析显示心电图异常与cTnI、TFF1、化疗剂量都存在相关性（P<0.05）。受试者工作特征（receiver operating characteristic，ROC）曲线显示cTnI、TFF1预测心电图异常的曲线下面积分别为0.782、0.706。结论：乳腺癌患者使用蒽环类药物化疗存在一定的心脏毒性反应，且存在剂量依赖性，血清cTnI、TFF1检测能有效预测化疗相关心脏毒性的发生，具有很好的临床应用价值。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the value of serum cardiac troponin I (Cardiac, Troponin I, cTnI) and trefoil factor 1 (trefoil factor 1, TFF1) in the prediction of breast cancer chemotherapy-related cardiotoxicity. Methods: According to the cumulative dose of epirubicin chemotherapy, 122 breast cancer patients were divided into low-dose group (450-500 mg/m2) 70 cases, medium-dose group (501-550 mg/m2) 30 cases, and high-dose group (>550 mg/m2) 22 cases. The serum cTnI and TFF1 levels were detected before chemotherapy, Observed the occurrence of cardiotoxicity and analyzed the predictive value after 4 cycles of chemotherapy. Results: 122 patients were divided into low-dose group of 70 cases, medium-dose group of 30 cases, and high-dose group of 22 cases accorded to the chemotherapy dose. There were no significant difference in the serum cTnI and TFF1 levels compared among the three groups before chemotherapy(P>0.05). The abnormal rate of ECG after chemotherapy in the low-dose group, middle-dose group and high-dose group were 1.4 %, 13.3 % and 22.7 %, respectively, and compared the difference were statistically significant(P<0.05). In the 122 patients, Pearson analysis showed that ECG abnormalities were correlated with cTnI, TFF1 and chemotherapy dose (P<0.05). The receiver operating characteristic(ROC) curve showed that the area under the curve for cTnI and TFF1 for predicting abnormal ECG were 0.782 and 0.706, respectively. Conclusion: The use of anthracycline chemotherapy in breast cancer patients have certain cardiotoxicity and are dose-dependent. The detection of serum cTnI and TFF1 can effectively predict the occurrence of chemotherapy-related cardiotoxicity and have good clinical application value. |
|
View Full Text
View/Add Comment Download reader |
| Close |
